Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
Abstract
The synthesis and structure-activity relationship of a novel series of compounds with combined effects on 5-HT(3A) and 5-HT(1A) receptors and on the serotonin (5-HT) transporter (SERT) are described. Compound 5m (Lu AA21004) was the lead compound, displaying high affinity for recombinant human 5-HT(1A) (K(i) = 15 nM), 5-HT(1B) (K(i) = 33 nM), 5-HT(3A) (K(i) = 3.7 nM), 5-HT(7) (K(i) = 19 nM), and noradrenergic β(1) (K(i) = 46 nM) receptors, and SERT (K(i) = 1.6 nM). Compound 5m displayed antagonistic properties at 5-HT(3A) and 5-HT(7) receptors, partial agonist properties at 5-HT(1B) receptors, agonistic properties at 5-HT(1A) receptors, and potent inhibition of SERT. In conscious rats, 5m significantly increased extracellular 5-HT levels in the brain after acute and 3 days of treatment. Following the 3-day treatment (5 or 10 (mg/kg)/day) SERT occupancies were only 43% and 57%, respectively. These characteristics indicate that 5m is a novel multimodal serotonergic compound, and 5m is currently in clinical development for major depressive disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The in vivo nonclinical studies in rodents have demonstrated that vortioxetine modulates serotonergic, noradrenergic, dopaminergic, cholinergic, histaminergic, and glutamatergic neurotransmission, affecting the levels of neurotransmitters involved in cognitive processes (Bang-Andersen et al, 2011; Mork et al, 2012, 2013; Pehrson et al, 2013; Pehrson and Sanchez, 2014; Wallace et al, 2014).”
From A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder (2015) · cites this paper as Bang-Andersen et al, 2011
In the citing paper
“The antidepressant vortioxetine, developed by Lundbeck and Takeda and approved in 2013, is a 5-HT 3 , 5-HT 7 and 5-HT 1D receptor antagonist, a 5-HT 1B receptor partial agonist, a 5-HT 1A receptor agonist and an inhibitor of the 5-HT transporter (Bang-Andersen et al., 2011) with a good tolerability and long-term safety profile and no evidence of sexual dysfunction as a side effect.”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Bang-Andersen et al., 2011
In the citing paper
“Vortioxetine (Lu AA21004) is an antidepressant that acts as an antagonist of the 5-HT3 and 5-HT7 serotonin receptors, partial agonist of the 5-HT1B serotonin receptor, agonist of the 5-HT1A receptor, and inhibits the serotonin transporter [88].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [88]
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Are the Dorsal and Ventral Hippocampus Functionally Distinct Structures?
Fanselow, M. S., & Dong, H.-W. (2010) · Neuron · doi:10.1016/j.neuron.2009.11.031 · Cited by 3,358
Drevets, W. C., Price, J. L., & Furey, M. L. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0189-x · Cited by 2,241
Evidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
Designed Multiple Ligands. An Emerging Drug Discovery Paradigm
Morphy, R., & Rankovic, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,209
A Simple Catalytic Method for the Conversion of Aryl Bromides to Arylamines
Guram, A. S., Rennels, R. A., & Buchwald, S. L. (1995) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199513481 · Cited by 1,070
Louie, J., & Hartwig, J. F. (1995) · Tetrahedron Letters · doi:10.1016/0040-4039(95)00605-c · Cited by 914
Is there a role for 5-HT1A agonists in the treatment of depression?
Blier, P., & Ward, N. M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01643-8 · Cited by 529
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Research works printed but not linked: 3
- Lenox R. H., 2002, Neuropsychopharmacology: The Fifth Generation of Progress: An Official Publication of the American College of Neuropsychopharmacology, 1139
- Moore N. A., 2008, Neuropsychopharmacology, 18, S321, 10.1016/s0924-977x(08)70440-1 · DOI
- Brunello N., 2003, Int. Clin. Psychopharmacol., 18, 191, 10.1097/01.yic.0000073880.93678.68 · doi:10.1097/01.yic.0000073880.93678.68 · Paper page
Cited by
Items 401–500 of 628
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.046 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.055 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.071 · Cited by 1
Regioselective Functionalization of Arenes Using Iron Triflimide Catalysis
Sutherland, A. J., Dodds, A. C., & Waddell, L. J. N. (2023) · Synlett · doi:10.1055/s-0042-1751445 · Cited by 1
Li, Q., Guo, Q., Ren, L., Zhao, S., Luo, J., Zhang, Y., Zhou, W., Xu, X., & Chen, G. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117935 · Cited by 1
Mendez‐David, I. (2013) · theses.fr (ABES) · doi:10.70675/3b74ce4cz68acz4446zbe46zb1542d4e9391 · Cited by 1
Lecours, M. (2013) · uO Research (University of Ottawa) · doi:10.20381/ruor-3484
SEROTONIN IN EMOTIONAL MEMORY PROCESSES: NEUROPHARMACOLOGICAL STUDIES WITH EMPHASIS ON DEPRESSION
Eriksson, T. (2012) · Figshare
Cuboni, S., & Hausch, F. (2014) · Angewandte Chemie · doi:10.1002/ange.201310567
Future perspectives on the pharmacological management of depression
Yates, S., Smith, E., Alhaj, H. A., & McAllister-Williams, H. (2013) · Clinical Investigation · doi:10.4155/cli.12.152
Zirngibl, C. (2014) · Journal of Depression & Anxiety · doi:10.4172/2167-1044.1000154
Antidepressivum mit unterschiedlichen Zielstrukturen und Wirkmechanismen
Volz, H. (2015) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-015-0928-9
“Vielmehr deuten die vorliegenden Befunde darauf hin, dass die antagonistische Funktion von Vortioxetin am 5HT1D-Rezeptor zusammen mit der partiell agonistischen Funktion am 5-HT1B-, der agonistischen Wirkweise am 5HT1A- sowie des Antagonismus am 5-HT3- und 5-HT7-Rezeptor der Substanz gemeinsam zu dem beobachteten pham…”
BackgroundBeyond SSRIs: Second-generation Reuptake Inhibitors for the Treatment of Depression
Gallagher, P. T. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00184
Multi-target Drug Discovery for Psychiatric Disorders
Ranković, Z., & Morphy, R. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00510 · Cited by 1
Iskandarani, E. (2014) · uO Research (University of Ottawa) · doi:10.20381/ruor-3466 · Cited by 1
Loland, C. J., Sánchez, C., Plenge, P., Bøgesø, K. P., & Bang‐Andersen, B. (2016) · Royal Society of Chemistry eBooks · doi:10.1039/9781782629276-00360
Self-citationNew Trends in Antidepressant Drug Research
Bang‐Andersen, B., Bøgesø, K. P., Kehler, J., & Sánchez, C. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527679430.ch2 · Cited by 1
Self-citationVortioxetin — ein neues Antidepressivum?
Cseh, S., Köppl, A., Stegmann, B., & Haen, E. (2016) · NeuroTransmitter · doi:10.1007/s15016-016-5486-7
PET studies on the mechanisms of action of antidepressant and antipsychotic drugs
Yang, K. (2017) · Figshare
Vortioxetine and Early Drug Development Considerations at the Interface of R&D
Jørgensen, M., Christensen, K., Juhl, M., & Bang‐Andersen, B. (2018) · Methods and principles in medicinal chemistry · doi:10.1002/9783527801756.ch6
Self-citationMedication-Associated Sexual Dysfunction in Patients with Mental Illness
Cuomo, A., Goracci, A., & Fagiolini, A. M. (2018) · Trends in andrology and sexual medicine · doi:10.1007/978-3-319-68306-5_21
Newer Updates in Psychiatry: Focus on Vortioxetine
Paul, I. (2018) · Indian Journal of Private Psychiatry · doi:10.5005/jp-journals-10067-0024
Faye, C. (2019) · theses.fr (ABES) · doi:10.70675/b3ef3280z5adbz4bf3za491zddb2cbdf6aa0 · Cited by 1
5-HT3 receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
Barnes, N. M., Hales, T. G., Lummis, S. C. R., Niesler, B., & Peters, J. A. (2019) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f68/2019.4
Hamati, R. (2020) · uO Research (University of Ottawa) · doi:10.20381/ruor-24287
Zhou, S. (2018) · CRC Press eBooks · doi:10.1201/9781315372983-3
5-HT3 receptors in GtoPdb v.2021.3
Barnes, N. M., Hales, T. G., Lummis, S. C. R., Niesler, B., & Peters, J. A. (2021) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f68/2021.3
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.009
Peripheral biomarkers in Repeated Ketamine Infusions Trial
Geel, A. V. (2021) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2021-14775
(2016) · CRC Press eBooks · doi:10.1201/b19643-4
Patel, D. H., & Pathak, D. (2022) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2022/v34i8b35479
“It is then typically further investigated by medical imaging and confirmed by biopsy [4-5].”
BackgroundStahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.058
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.051
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.007
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0112
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.008
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.097
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0138
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.082
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.074
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0145
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.093
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.028
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0108
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0130
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.026
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.029
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0122
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0107
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.035
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.015
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0150
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.044
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.001
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.034
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0128
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.089
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.016
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0105
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.049
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.061
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.048
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.019
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0135
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0156
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.066
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0131
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.052
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.031
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0142
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.014
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.075
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.043
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.077
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.063
Kleemann, A. (2019) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.p02_p01.pub2
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.064
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.081
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.078
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0153
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.054
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.037
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0106
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.021
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0124
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.090
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.062
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.020
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.088
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.070
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0103
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.011
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.080
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0154
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.095
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0123
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.094
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.073
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0129
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.098
Metadata
- Authors
- Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., & Stensbøl, T. B.
- Affiliations
- Neuroscience Drug Discovery Denmark, H. Lundbeck A/S, 9 Ottiliavej, DK-2500 Copenhagen-Valby, Denmark
- Lundbeck (Denmark) (DK)
- Lundbeck (United States) (US)
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-04-12
- Volume
- 54
- Issue
- 9
- Pages
- 3206-3221
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2036812642
- Cited by
- 606
- References
- 58
- Citations by year
- 2026: 20 · 2025: 26 · 2024: 24 · 2023: 33 · 2022: 27 · 2021: 27 · 2020: 181 · 2019: 32 · 2018: 21 · 2017: 37 · 2016: 37 · 2015: 53 · 2014: 35 · 2013: 25 · 2012: 21
- FWCI
- 21.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- vortioxetine, major depressive disorder, multimodal antidepressant, 5-HT3 receptor antagonists, 5-HT1A receptor, 5-HT1B receptor, 5-HT7 receptor, serotonin transporter inhibition, structure-activity relationship, piperazine derivatives
- MeSH terms
- Vortioxetine, Animals, Antidepressive Agents, Cell Line, Major Depressive Disorder, Depressive Disorder, Major, Drug Stability, Hippocampus, Humans, Microsomes, Liver, Oocytes, Piperazines, Radioligand Assay, Receptors, Serotonin, Recombinant Proteins, Serotonin, Structure-Activity Relationship, Sulfides, Xenopus, Selective Serotonin Reuptake Inhibitors, Receptors, Serotonin, 5-HT1, Receptor, Serotonin, 5-HT1A, Receptor, Serotonin, 5-HT2C, Receptors, Serotonin, 5-HT3, Serotonin Plasma Membrane Transport Proteins, Rats, Drug Partial Agonism, Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT3 Receptor Antagonists, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.